By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Canopus BioPharma, Inc. 

11825 Ventura Boulevard

Studio City  California  91604  U.S.A.
Phone: 818-980-5008 Fax: 818-980-5088


Company News
Canopus BioPharma, Inc. Announces Positive Results From An In-Vitro Live Ebola Virus Study 12/19/2014 8:46:21 AM
Canopus BioPharma, Inc. Announces Results From Compassionate Study In Hepatitis C Patients In China 7/1/2014 10:59:05 AM
Major Influenza Pandemic Threat is now Preventable and Treatable with Canopus BioPharma, Inc.'s Aerosol Statin Formulation 5/12/2009 10:32:04 AM
Working with U.S. Department of Defense, Canopus BioPharma, Inc. Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300 11/4/2008 9:02:16 AM
Canopus BioPharma, Inc. Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine 11/3/2008 6:31:44 AM
Canopus BioPharma, Inc. and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic 8/12/2008 11:27:23 AM
CB1400, Patented by Canopus BioPharma, Inc., Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck 6/23/2008 7:43:55 AM
B1400, Patented by Canopus BioPharma, Inc., Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux) 6/19/2008 10:08:43 AM
Canopus BioPharma, Inc. Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement with Wisconsin Alumni Research Foundation (WARF) 6/18/2008 10:05:11 AM
Canopus BioPharma, Inc. to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo 5/15/2008 10:15:29 AM